Iron as a target of chemoprevention for longevity in humans

References

• Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B, Demetri GD. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1052–1056.
   PubMed Web of Science ®Google Scholar
• Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290:2149–2158.
   PubMed Web of Science ®Google Scholar
• Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031–1037.
   PubMed Web of Science ®Google Scholar
• Soda M, Takada S, Takeuchi K, Choi YL, Enomoto M, Ueno T, Haruta H, Hamada T, Yamashita Y, Ishikawa Y, Sugiyama Y, Mano H. A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci USA 2008;105:19893–19897.
   PubMed Web of Science ®Google Scholar
• Hallberg B, Palmer RH. Crizotinib–latest champion in the cancer wars? N Engl J Med 2010;363:1760–1762.
   PubMed Web of Science ®Google Scholar
• Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673–1684.
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Grillo-Lopez AJ, White CA, Saleh M, Gordon L, Lo Buglio AF, Jonas C, Klippenstein D, Dallaire B, Varns C. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999;17:268–276.
   PubMed Web of Science ®Google Scholar
• Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T, Yatabe Y, Takeuchi K, Hamada T, Haruta H, Ishikawa Y, Kimura H, Mitsudomi T, Tanio Y, Mano H. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010;363:1734–1739.
   PubMed Web of Science ®Google Scholar
• Tolaney SM, Krop IE. Mechanisms of trastuzumab resistance in breast cancer. Anticancer Agents Med Chem 2009;9:348–355.
   PubMedGoogle Scholar
• Hsu FJ, Caspar CB, Czerwinski D, Kwak LW, Liles TM, Syrengelas A, Taidi-Laskowski B, Levy R. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma–long-term results of a clinical trial. Blood 1997;89:3129–3135.
   PubMed Web of Science ®Google Scholar
• Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131:861–872.
   PubMed Web of Science ®Google Scholar
• Carpiuc KT, Stephens JM, Botteman MF, Feng W, Hay JW. A review of the clinical and economic outcomes of imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia. Expert Opin Pharmacother 2007;8:2775–2787.
   PubMed Web of Science ®Google Scholar
• Reddy P, Boci K, Charbonneau C. The epidemiologic, health-related quality of life, and economic burden of gastrointestinal stromal tumours. J Clin Pharm Ther 2007;32:557–565.
   PubMed Web of Science ®Google Scholar
• Drucker A, Skedgel C, Virik K, Rayson D, Sellon M, Younis T. The cost burden of trastuzumab and bevacizumab therapy for solid tumours in Canada. Curr Oncol 2008;15:136–142.
   PubMed Web of Science ®Google Scholar
• Zacharski L, Ornstein D, Woloshin S, Schwartz L. Association of age, sex, and race with body iron stores in adults: analysis of NHANES III data. Am Heart J 2000;140: 98–104.
   PubMed Web of Science ®Google Scholar
• Wriggleworth JM, Baum H. The biochemical function of iron. Jacobs A, Worwood M. Iron in biochemistry and medicine, II. London: Academic Press; 1980. 29–86.
   Google Scholar
• Fenton HJH. Oxidation of tartaric acid in presence of iron. J Chem Soc 1894;65:899–910.
   Google Scholar
• Gutteridge JMC, Rowley DA, Halliwell B. Superoxide-dependent formation of hydroxyl radicals and lipid peroxidation in the presence of iron salts: detection of ‘catalytic’ iron and anti-oxidant activity in extracellular fluids. Biochem J 1982;206:605–609.
   PubMed Web of Science ®Google Scholar
• Thauer R, Jungermann K, Decker K. Energy conservation in chemotrophic anaerobic bacteria. Bacteriol Rev 1977; 41:100–180.
   PubMedGoogle Scholar
• Lippard SJ, Berg JM. Principles of bioorganic chemistry. Mill Valley, CA: University Science Books; 1994.
   Google Scholar
• Gutteridge JMC. Superoxide-dependent formation of hydroxyl radicals from ferric- complexes and hydrogen peroxide: an evaluation of fourteen iron chelators. Free Radic Res Comm 1990;9:119–125.
   PubMed Web of Science ®Google Scholar
• Graf E, Mahoney JR, Bryant RG, Eaton JW. Iron-catalyzed hydroxyl radical formation: stringent requirement for free iron coordination site. J Biol Chem 1984;259:3620–3624.
   PubMed Web of Science ®Google Scholar
• Toyokuni S, Sagripanti JL. Iron-mediated DNA damage: sensitive detection of DNA strand breakage catalyzed by iron. J Inorg Biochem 1992;47:241–248.
   PubMed Web of Science ®Google Scholar
• Geisser P. Iron therapy: with special emphasis on oxidaitive stress. Stuttgart: Georg Thieme Verlag; 1996.
   Google Scholar
• Hopkins CR. Intracellular routing of transferrin and transferrin receptors in epidermoid carcinoma A431 cells. Cell 1983;35:321–330.
   PubMed Web of Science ®Google Scholar
• Hentze M, Kuhn L. Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress. Proc Natl Acad Sci USA 1996;93:8175–8182.
   PubMed Web of Science ®Google Scholar
• Wheby MS, Jones LG, Crosby WH. Studies on iron absorption. Intestinal regulatory mechanisms. J Clin Invest 1964;43:1433–1442.
   PubMed Web of Science ®Google Scholar
• Gunshin H, Mackenzie B, Berger U, Gunshin Y, Romero M, Boron W, Nussberger S, Gollan J, Hediger M. Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature 1997;388:482–488.
   PubMed Web of Science ®Google Scholar
• Fleming M, Trenor C, Su M, Foernzler D, Beier D, Dietrich W, Andrews N. Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene. Nat Genet 1997;16:383–386.
   PubMed Web of Science ®Google Scholar
• McKie AT, Barrow D, Latunde-Dada GO, Rolfs A, Sager G, Mudaly E, Mudaly M, Richardson C, Barlow D, Bomford A, Peters TJ, Raja KB, Shirali S, Hediger MA, Farzaneh F, Simpson RJ. An iron-regulated ferric reductase associated with the absorption of dietary iron. Science 2001;291:1755–1759.
   PubMed Web of Science ®Google Scholar
• Fleming M, Romano M, Su M, Garrick L, Garrick M, Andrews N. Nramp2 is mutated in the anemic Belgrade (b) rat: evidence of a role for Nramp2 in endosomal iron transport. Proc Natl Acad Sci USA 1998;95:1148–1153.
   PubMed Web of Science ®Google Scholar
• Mims M, Guan Y, Pospisilova D, Priwitzerova M, Indrak K, Ponka P, Divoky V, Prchal J. Identification of a human mutation of DMT1 in a patient with microcytic anemia and iron overload. Blood 2005;105:1337–1342.
   PubMed Web of Science ®Google Scholar
• Iolascon A, d’Apolito M, Servedio V, Cimmino F, Piga A, Camaschella C. Microcytic anemia and hepatic iron overload in a child with compound heterozygous mutations in DMT1 (SCL11A2). Blood 2006;107:349–354.
   PubMed Web of Science ®Google Scholar
• Gunshin H, Fujiwara Y, Custodio A, Direnzo C, Robine S, Andrews N. Slc11a2 is required for intestinal iron absorption and erythropoiesis but dispensable in placenta and liver. J Clin Invest 2005;115:1258–1266.
   PubMed Web of Science ®Google Scholar
• McKie A, Marciani P, Rolfs A, Brennan K, Wehr K, Barrow D, Miret S, Bomford A, Peters T, Farzaneh F, Hediger M, Hentze M, Simpson R. A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. Mol Cell 2000;5:299–309.
   PubMed Web of Science ®Google Scholar
• Donovan A, Brownlie A, Zhou Y, Shepard J, Pratt S, Moynihan J, Paw B, Drejer A, Barut B, Zapata A, Law T, Brugnara C, Lux S, Pinkus G, Pinkus J, Kingsley P, Palis J, Fleming M, Andrews N, Zon L. Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature 2000;403:776–781.
   PubMed Web of Science ®Google Scholar
• Abboud S, Haile D. A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J Biol Chem 2000;275:19906–19912.
   PubMed Web of Science ®Google Scholar
• Shirase T, Mori K, Okazaki Y, Itoh K, Yamamoto M, Tabuchi M, Kishi F, Jiang L, Akatsuka S, Nakao K, Toyokuni S. Suppression of SLC11A2 expression is essential to maintain duodenal integrity during dietary iron overload. Am J Pathol 2010;177:677–685.
   PubMed Web of Science ®Google Scholar
• Krause A, Neitz S, Magert HJ, Schulz A, Forssmann WG, Schulz-Knappe P, Adermann K. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett 2000;480:147–150.
   PubMed Web of Science ®Google Scholar
• Tomosugi N, Kawabata H, Wakatabe R, Higuchi M, Yamaya H, Umehara H, Ishikawa I. Detection of serum hepcidin in renal failure and inflammation by using ProteinChip System. Blood 2006;108:1381–1387.
   PubMed Web of Science ®Google Scholar
• Nemeth E, Preza G, Jung C, Kaplan J, Waring A, Ganz T. The N-terminus of hepcidin is essential for its interaction with ferroportin: structure-function study. Blood 2006;107:328–333.
   PubMed Web of Science ®Google Scholar
• Donovan A, Lima C, Pinkus J, Pinkus G, Zon L, Robine S, Andrews N. The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metab 2005;1:191–200.
   PubMed Web of Science ®Google Scholar
• Akerstrom B, Flower DR, Salier JP. Lipocalins: unity in diversity. Biochim Biophys Acta 2000;1482:1–8.
   PubMedGoogle Scholar
• Devireddy LR, Hart DO, Goetz DH, Green MR. A mammalian siderophore synthesized by an enzyme with a bacterial homolog involved in enterobactin production. Cell 2010;141: 1006–1017.
   PubMed Web of Science ®Google Scholar
• Bao G, Clifton M, Hoette TM, Mori K, Deng SX, Qiu A, Viltard M, Williams D, Paragas N, Leete T, Kulkarni R, Li X, Lee B, Kalandadze A, Ratner AJ, Pizarro JC, Schmidt-Ott KM, Landry DW, Raymond KN, Strong RK, Barasch J. Iron traffics in circulation bound to a siderocalin (Ngal)-catechol complex. Nat Chem Biol 2010;6:602–609.
   PubMed Web of Science ®Google Scholar
• Roudkenar MH, Kuwahara Y, Baba T, Roushandeh AM, Ebishima S, Abe S, Ohkubo Y, Fukumoto M. Oxidative stress induced lipocalin 2 gene expression: addressing its expression under the harmful conditions. J Radiat Res (Tokyo) 2007; 48:39–44.
   PubMed Web of Science ®Google Scholar
• Liu Y-T, Shang D-G, Akatsuka S, Ohara H, Dutta KK, Mizushima K, Naito Y, Yoshikawa T, Izumiya M, Abe K, Nakagama H, Noguchi N, Toyokuni S. Chronic oxidative stress causes amplification and overexpresson of ptprz1 protein tyrosine phosphatase to activate β-catenin pathway. Am J Pathol 2007;171:1978–1988.
   PubMedGoogle Scholar
• Dhaliwal B, Steinbrecher U. Scavenger receptors and oxidized low density lipoproteins. Clin Chim Acta 1999;286:191–205.
   PubMed Web of Science ®Google Scholar
• Davies MJ, Thomas AC. Plaque fissuring–the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J 1985;53:363–373.
   PubMedGoogle Scholar
• Sullivan JL. Iron and the sex difference in heart disease risk. Lancet 1981;1:1293–1294.
   PubMed Web of Science ®Google Scholar
• Kirk EA, Heinecke JW, Le Boeuf RC. Iron overload diminishes atherosclerosis in apoE-deficient mice. J Clin Invest 2001;107:1545–1553.
   PubMedGoogle Scholar
• Araujo JA, Romano EL, Brito BE, Parthe V, Romano M, Bracho M, Montano RF, Cardier J. Iron overload augments the development of atherosclerotic lesions in rabbits. Arterioscler Thromb Vasc Biol 1995;15:1172–1180.
   PubMed Web of Science ®Google Scholar
• Dabbagh AJ, Shwaery GT, Keaney JF, Frei B. Effect of iron overload and iron deficiency on atherosclerosis in the hypercholesterolemic rabbit. Arterioscler Thromb Vasc Biol 1997; 17:2638–2645.
   PubMedGoogle Scholar
• Niederau C. Iron overload and atherosclerosis. Hepatology 2000;32:672–674.
   PubMedGoogle Scholar
• Failla M, Giannattasio C, Piperno A, Vergani A, Grappiolo A, Gentile G, Meles E, Mancia G. Radial artery wall alterations in genetic hemochromatosis before and after iron depletion therapy. Hepatology 2000;32:569–573.
   PubMed Web of Science ®Google Scholar
• Sullivan JL. Iron in arterial plaque: modifiable risk factor for atherosclerosis. Biochim Biophys Acta 2009;1790:718–723.
   PubMed Web of Science ®Google Scholar
• Stadler N, Lindner RA, Davies MJ. Direct detection and quantification of transition metal ions in human atherosclerotic plaques: evidence for the presence of elevated levels of iron and copper. Arterioscler Thromb Vasc Biol 2004;24:949–954.
   PubMed Web of Science ®Google Scholar
• Lee TS, Shiao MS, Pan CC, Chau LY. Iron-deficient diet reduces atherosclerotic lesions in apoE-deficient mice. Circulation 1999;99:1222–1229.
   PubMed Web of Science ®Google Scholar
• Lee HT, Chiu LL, Lee TS, Tsai HL, Chau LY. Dietary iron restriction increases plaque stability in apolipoprotein-e-deficient mice. J Biomed Sci 2003;10:510–517.
   PubMedGoogle Scholar
• Moreno PR, Purushothaman KR, Purushothaman M, Muntner P, Levy NS, Fuster V, Fallon JT, Lento PA, Winterstern A, Levy AP. Haptoglobin genotype is a major determinant of the amount of iron in the human atherosclerotic plaque. J Am Coll Cardiol 2008;52:1049–1051.
   PubMedGoogle Scholar
• Chen YH, Lin SJ, Lin MW, Tsai HL, Kuo SS, Chen JW, Charng MJ, Wu TC, Chen LC, Ding YA, Pan WH, Jou YS, Chau LY. Microsatellite polymorphism in promoter of heme oxygenase-1 gene is associated with susceptibility to coronary artery disease in type 2 diabetic patients. Hum Genet 2002;111:1–8.
   PubMed Web of Science ®Google Scholar
• Chen YH, Chau LY, Chen JW, Lin SJ. Serum bilirubin and ferritin levels link heme oxygenase-1 gene promoter polymorphism and susceptibility to coronary artery disease in diabetic patients. Diabetes Care 2008;31:1615–1620.
   PubMed Web of Science ®Google Scholar
• Sullivan JL. Macrophage iron, hepcidin, and atherosclerotic plaque stability. Exp Biol Med (Maywood) 2007;232: 1014–1020.
   PubMed Web of Science ®Google Scholar
• Nemeth E, Ganz T. Regulation of iron metabolism by hepcidin. Annu Rev Nutr 2006;26:323–342.
   PubMed Web of Science ®Google Scholar
• Kawai Y, Tanaka H, Murota K, Naito M, Terao J. (-)-Epicatechin gallate accumulates in foamy macrophages in human atherosclerotic aorta: implication in the anti-atherosclerotic actions of tea catechins. Biochem Biophys Res Commun 2008;374:527–532.
   PubMed Web of Science ®Google Scholar
• Kawai Y, Nishikawa T, Shiba Y, Saito S, Murota K, Shibata N, Kobayashi M, Kanayama M, Uchida K, Terao J. Macrophage as a target of quercetin glucuronides in human atherosclerotic arteries: implication in the anti-atherosclerotic mechanism of dietary flavonoids. J Biol Chem 2008;283:9424–9434.
   PubMed Web of Science ®Google Scholar
• Drakesmith H, Prentice A. Viral infection and iron metabolism. Nat Rev Microbiol 2008;6:541–552.
   PubMed Web of Science ®Google Scholar
• Kato J, Kobune M, Nakamura T, Kuroiwa G, Takada K, Takimoto R, Sato Y, Fujikawa K, Takahashi M, Takayama T, Ikeda T, Niitsu Y. Normalization of elevated hepatic 8-hydroxy-2’-deoxyguanosine levels in chronic hepatitis C patients by phlebotomy and low iron diet. Cancer Res 2001;61:8697–8702.
   PubMed Web of Science ®Google Scholar
• Kato J, Miyanishi K, Kobune M, Nakamura T, Takada K, Takimoto R, Kawano Y, Takahashi S, Takahashi M, Sato Y, Takayama T, Niitsu Y. Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. J Gastroenterol 2007;42:830–836.
   PubMed Web of Science ®Google Scholar
• Nishina S, Hino K, Korenaga M, Vecchi C, Pietrangelo A, Mizukami Y, Furutani T, Sakai A, Okuda M, Hidaka I, Okita K, Sakaida I. Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription. Gastroenterology 2008;134:226–238.
   PubMed Web of Science ®Google Scholar
• Pathology of asbestos-associated diseases. Roggli VL, Oury TD, Sporn TA. 2nd. New York: Springer Verlag; 2004.
   Google Scholar
• McDonald A, McDonald J, Pooley F. Mineral fibre content of lung in mesothelial tumours in North America. Ann Occup Hyg 1982;26:417–422.
   PubMed Web of Science ®Google Scholar
• Jiang L, Nagai H, Ohara H, Hara S, Tachibana M, Hirano S, Shinohara Y, Kohyama N, Akatsuka S, Toyokuni S. Characteristics and modifying factors of asbestos-induced oxidative DNA damage. Cancer Sci 2008;99:2142–2151.
   PubMed Web of Science ®Google Scholar
• Smith AH, Wright CC. Chrysotile asbestos is the main cause of pleural mesothelioma. Am J Ind Med 1996;30:252–266.
   PubMed Web of Science ®Google Scholar
• Brinton L, Gridley G, Persson I, Baron J, Bergqvist A. Cancer risk after a hospital discharge diagnosis of endometriosis. Am J Obstet Gynecol 1997;176:572–579.
   PubMed Web of Science ®Google Scholar
• Fukunaga M, Nomura K, Ishikawa E, Ushigome S. Ovarian atypical endometriosis: its close association with malignant epithelial tumours. Histopathology 1997;30:249–255.
   PubMed Web of Science ®Google Scholar
• Yamaguchi K, Mandai M, Toyokuni S, Hamanishi J, Higuchi T, Takakura K, Fujii S. Contents of endometriotic cysts, especially the high concentration of free iron, are a possible cause of carcinogenesis in the cysts through the iron-induced persistent oxidative stress. Clin Cancer Res 2008;14: 32–40.
   PubMed Web of Science ®Google Scholar
• Campbell JA. Effects of precipitated silica and of iron oxide on the incidence of primary lung tumours in mice. Br Med J August 1940;31:275–280.
   Google Scholar
• Richmond HG. Induction of sarcoma in the rat by iron- dextran complex. Br Med J 1959;i:947–949.
   Google Scholar
• Ebina Y, Okada S, Hamazaki S, Ogino F, Li JL, Midorikawa O. Nephrotoxicity and renal cell carcinoma after use of iron- and aluminum- nitrilotriacetate complexes in rats. J Natl Cancer Inst 1986;76:107–113.
   PubMed Web of Science ®Google Scholar
• Li JL, Okada S, Hamazaki S, Ebina Y, Midorikawa O. Subacute nephrotoxicity and induction of renal cell carcinoma in mice treated with ferric nitrilotriacetate. Cancer Res 1987;47:1867–1869.
   PubMed Web of Science ®Google Scholar
• Toyokuni S, Okada S, Hamazaki S, Minamiyama Y, Yamada Y, Liang P, Fukunaga Y, Midorikawa O. Combined histochemical and biochemical analysis of sex hormone dependence of ferric nitrilotriacetate-induced renal lipid peroxidation in ddY mice. Cancer Res 1990;50: 5574–5580.
   PubMed Web of Science ®Google Scholar
• Toyokuni S, Uchida K, Okamoto K, Hattori-Nakakuki Y, Hiai H, Stadtman ER. Formation of 4-hydroxy-2-nonenal-modified proteins in the renal proximal tubules of rats treated with a renal carcinogen, ferric nitrilotriacetate. Proc Natl Acad Sci USA 1994;91:2616–2620.
   PubMed Web of Science ®Google Scholar
• Toyokuni S, Tanaka T, Hattori Y, Nishiyama Y, Ochi H, Hiai H, Uchida K, Osawa T. Quantitative immunohistochemical determination of 8-hydroxy-2’-deoxyguanosine by a monoclonal antibody N45.1: its application to ferric nitrilotriacetate-induced renal carcinogenesis model. Lab Invest 1997;76:365–374.
   PubMed Web of Science ®Google Scholar
• Toyokuni S, Luo XP, Tanaka T, Uchida K, Hiai H, Lehotay DC. Induction of a wide range of C2-12 aldehydes and C7-12 acyloins in the kidney of Wistar rats after treatment with a renal carcinogen, ferric nitrilotriacetate. Free Radic Biol Med 1997;22:1019–1027.
   PubMed Web of Science ®Google Scholar
• Okada S, Hamazaki S, Toyokuni S, Midorikawa O. Induction of mesothelioma by intraperitoneal injections of ferric saccharate in male Wistar rats. Br J Cancer 1989;60:708–711.
   PubMed Web of Science ®Google Scholar
• Nishiyama Y, Suwa H, Okamoto K, Fukumoto M, Hiai H, Toyokuni S. Low incidence of point mutations in H-, K- and N-ras oncogenes and p53 tumor suppressor gene in renal cell carcinoma and peritoneal mesothelioma of Wistar rats induced by ferric nitrilotriacetate. Jpn J Cancer Res 1995;86: 1150–1158.
   PubMedGoogle Scholar
• Toyokuni S, Mori T, Dizdaroglu M. DNA base modifications in renal chromatin of Wistar rats treated with a renal carcinogen, ferric nitrilotriacetate. Int J Cancer 1994;57:123–128.
   PubMed Web of Science ®Google Scholar
• Toyokuni S, Mori T, Hiai H, Dizdaroglu M. Treatment of Wistar rats with a renal carcinogen, ferric nitrilotriacetate, causes DNA-protein cross-linking between thymine and tyrosine in their renal chromatin. Int J Cancer 1995;62:309–313.
   PubMed Web of Science ®Google Scholar
• Jiang L, Zhong Y, Akatsuka S, Liu Y, Dutta K, Lee W, Onuki J, Masumura K, Nohmi T, Toyokuni S. Deletion and single nucleotide substitution at G:C in the kidney of gpt delta transgenic mice after ferric nitrilotriacetate treatment. Cancer Sci 2006;97: 1159–1167.
   PubMed Web of Science ®Google Scholar
• Tanaka T, Iwasa Y, Kondo S, Hiai H, Toyokuni S. High incidence of allelic loss on chromosome 5 and inactivation of p15INK4B and p16INK4A tumor suppressor genes in oxystress-induced renal cell carcinoma of rats. Oncogene 1999;18:3793–3797.
   PubMed Web of Science ®Google Scholar
• Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, Sherr CJ. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci USA 1998;95:8292–8297.
   PubMed Web of Science ®Google Scholar
• Honda R, Yasuda H. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J 1999;18:22–27.
   PubMed Web of Science ®Google Scholar
• Hiroyasu M, Ozeki M, Kohda H, Echizenya M, Tanaka T, Hiai H, Toyokuni S. Specific allelic loss of p16INK4A tumor suppressor gene after weeks of iron-mediated oxidative damage during rat renal carcinogenesis. Am J Pathol 2002; 160:419–424.
   PubMed Web of Science ®Google Scholar
• Akatsuka S, Aung TT, Dutta KK, Jiang L, Lee WH, Liu YT, Onuki J, Shirase T, Yamasaki K, Ochi H, Naito Y, Yoshikawa T, Kasai H, Tominaga Y, Sakumi K, Nakabeppu Y, Kawai Y, Uchida K, Yamasaki A, Tsuruyama T, Yamada Y, Toyokuni S. Contrasting genome-wide distribution of 8-hydroxyguanine and acrolein-modified adenine during oxidative stress-induced renal carcinogenesis. Am J Pathol 2006;169:1328–1342.
   PubMed Web of Science ®Google Scholar
• Ottolenghi A, Joseph L, Newman H, Stephens R. Interaction of erythrocyte membranes with particulates. Environ Health Perspect 1983;51:253–256.
   PubMedGoogle Scholar
• Lee W, Testa J. Somatic genetic alterations in human malignant mesothelioma (review). Int J Oncol 1999;14:181–188.
   PubMed Web of Science ®Google Scholar
• Hu Q, Akatsuka S, Yamashita Y, Ohara H, Nagai H, Okazaki Y, Takahashi T, Toyokuni S. Homozygous deletion of CDKN2A/2B is a hallmark of iron-induced high-grade rat mesothelioma. Lab Invest 2010;90:360–373.
   PubMed Web of Science ®Google Scholar
• Toyokuni S, Okamoto K, Yodoi J, Hiai H. Persistent oxidative stress in cancer. FEBS Lett 1995;358:1–3.
   PubMed Web of Science ®Google Scholar
• Meerlo P, Mistlberger RE, Jacobs BL, Heller HC, McGinty D. New neurons in the adult brain: the role of sleep and consequences of sleep loss. Sleep Med Rev 2009;13:187–194.
   PubMed Web of Science ®Google Scholar
• Bradbury MW. Transport of iron in the blood-brain-cerebrospinal fluid system. J Neurochem 1997;69:443–454.
   PubMed Web of Science ®Google Scholar
• Gordeuk V, Thuma P, Brittenham G, McLaren C, Parry D, Backenstose A, Biemba G, Msiska R, Holme L, McKinley E, Vargas L, Gilkeso R, Poltera AA. Effect of iron chelation therapy on recovery from deep coma in children with cerebral malaria. N Engl J Med 1992;327:1473–1477.
   PubMed Web of Science ®Google Scholar
• Butensky E, Kennedy CM, Lee MM, Harmatz P, Miaskowski C. Potential mechanisms for altered iron metabolism in human immunodeficiency virus disease. J Assoc Nurses AIDS Care 2004;15:31–45.
   PubMed Web of Science ®Google Scholar
• Taylor TD, Litt M, Kramer P, Pandolfo M, Angelini L, Nardocci N, Davis S, Pineda M, Hattori H, Flett PJ, Cilio MR, Bertini E, Hayflick SJ. Homozygosity mapping of Hallervorden-Spatz syndrome to chromosome 20p12.3-p13. Nat Genet 1996;14:479–481.
   PubMed Web of Science ®Google Scholar
• Zhou B, Westaway SK, Levinson B, Johnson MA, Gitschier J, Hayflick SJ. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat Genet 2001;28:345–349.
   PubMed Web of Science ®Google Scholar
• Miyajima H. Aceruloplasminemia, an iron metabolic disorder. Neuropathology 2003;23:345–350.
   PubMed Web of Science ®Google Scholar
• Gotz ME, Double K, Gerlach M, Youdim MB, Riederer P. The relevance of iron in the pathogenesis of Parkinson’s disease. Ann N Y Acad Sci 2004;1012:193–208.
   PubMed Web of Science ®Google Scholar
• Moos T, Morgan EH. The metabolism of neuronal iron and its pathogenic role in neurological disease: review. Ann N Y Acad Sci 2004;1012:14–26.
   PubMed Web of Science ®Google Scholar
• Duce JA, Tsatsanis A, Cater MA, James SA, Robb E, Wikhe K, Leong SL, Perez K, Johanssen T, Greenough MA, Cho HH, Galatis D, Moir RD, Masters CL, McLean C, Tanzi RE, Cappai R, Barnham KJ, Ciccotosto GD, Rogers JT, Bush AI. Iron-export ferroxidase activity of beta-amyloid precursor protein is inhibited by zinc in Alzheimer’s disease. Cell 2010;142:857–867.
   PubMed Web of Science ®Google Scholar
• Becker E, Richardson D. Frataxin: its role in iron metabolism and the pathogenesis of Friedreich’s ataxia. Int J Biochem Cell Biol 2001;33:1–10.
   PubMed Web of Science ®Google Scholar
• Miceli MH, Dong L, Grazziutti ML, Fassas A, Thertulien R, Van Rhee F, Barlogie B, Anaissie EJ. Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients. Bone Marrow Transplant 2006;37:857–864.
   PubMed Web of Science ®Google Scholar
• Kalinowski DS, Richardson DR. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev 2005;57:547–583.
   PubMed Web of Science ®Google Scholar
• Zacharski L, Chow B, Howes P, Shamayeva G, Baron J, Dalman R, Malenka D, Ozaki C, Levori P. Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial. J Natl Cancer Inst 2008;100:996–1002.
   PubMed Web of Science ®Google Scholar
• Edgren G, Nyren O, Melbye M. Cancer as a ferrotoxic disease: are we getting hard stainless evidence? J Natl Cancer Inst 2008;100:976–977.
   PubMedGoogle Scholar
• Edgren G, Reilly M, Hjalgrim H, Tran T, Rostgaard K, Adami J, Titlestad K, Shanwell A, Melbye M, Nyren O. Donation frequency, iron loss, and risk of cancer among blood donors. J Natl Cancer Inst 2008;100:572–579.
   PubMed Web of Science ®Google Scholar
• Toyokuni S. Iron-induced carcinogenesis: the role of redox regulation. Free Radic Biol Med 1996;20:553–566.
   PubMed Web of Science ®Google Scholar
• Wu T, Sempos C, Freudenheim J, Muti P, Smit L. Serum iron, copper and zinc concentrations and risk of cancer mortality in US adults. Ann Epidemiol 2004;14:195–201.
   PubMed Web of Science ®Google Scholar
• Zacharski L, Chow B, Howes P, Shamayeva G, Baron J, Dalman R, Malenka D, Ozaki C, Lavori P. Reduction of iron stores and cardiovascular outcomes in patients with peripheral arterial disease: a randomized controlled trial. JAMA 2007;297:603–610.
   PubMed Web of Science ®Google Scholar
• Nishida Y, Yoshizawa K, AKamatsu T. Preparation of iron(III) comple with nitrilotriacetic acid and origin of its unique reactivity. Chem Lett 1991;20:1521–1524.
   Google Scholar